Clinical research progress in tumor hypoxia imaging agent 18F-FMISO

WANG Shu; LI Ya-ming

Journal of China Clinic Medical Imaging ›› 2018, Vol. 29 ›› Issue (1) : 58-60.

WANG Shu, LI Ya-ming

Author information +

History +

Abstract

Hypoxia is an important characteristic of malignant tumor. Its occurrence depends on tumor angiogenesis and rapid growth of tumor cells, which will cause the imbalance of oxygen supply and oxygen consumption in the tumor. Tumor hypoxia can not only make itself more aggressive, but also cause resistance to chemotherapy and radiotherapy. 18F-fluorine nitroimidazole(18F-FMISO) can reflect the hypoxic conditions in tumor better. However, it will be influenced by the environment and other drugs. With the more understanding of tumor hypoxia imaging agent 18F-FMISO and its influence factors, the management of cancer patients will be improved with personalized treatment and efficacy evaluation.

Key words

Neoplasms / Contrast media

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Shu, LI Ya-ming. Clinical research progress in tumor hypoxia imaging agent 18F-FMISO[J]. Journal of China Clinic Medical Imaging. 2018, 29(1): 58-60

References

[1]Muz B, de la Puente P, Azab F, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy[J]. Hypoxia(Auckl), 2015, 3: 83-92.
[2]Deep G, Panigrahi GK. Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment[J]. Crit Rev Oncog, 2015, 20(5-6): 419-434.
[3]Yoshimura M, Itasaka S, Harada H, et al. Microenvironment and radiation therapy[J]. Biomed Res Int, 2013, 2013: 685308.
[4]Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer[J]. Pharmacol Ther, 2016, 164: 152-169.
[5]Wijsman R, Kaanders JH, Oyen WJ, et al. Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography[J]. Q J Nucl Med Mol Imaging, 2013, 57(3): 244-256.
[6]Karakashev SV, Reginato MJ. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2[J]. Oncotarget, 2015, 6(4): 1967-1980.
[7]Son B, Lee S, Youn H, et al. The role of tumor microenvironment in therapeutic resistance[J]. Oncotarget, 2016, 8(3): 3933-3945.
[8]Bourgeois M, Rajerison H, Guerard F, et al. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical[18F]-MISO—a selected review[J]. Nucl Med Rev Cent East Eur, 2011, 14(2): 90-95.
[9]Hoigebazar L, Jeong JM. Hypoxia imaging agents labeled with positron emitters[J]. Recent Results Cancer Res, 2013, 194: 285-299.
[10]Wang W, Lee NY, Georgi JC, et al. Pharmacokinetic analysis of hypoxia 18F-fluoromisonidazole dynamic PET in head and neck cancer[J]. J Nucl Med, 2010, 51(1): 37-45.
[11]Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emissiontomography[J]. BJU Int, 2005, 96(4): 540-546.
[12]Zimny M, Gagel B, DiMartino E, et al. FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer[J]. Eur J Nucl Med Mol Imaging, 2006, 33(12): 1426-1431.
[13]Bejot R, Kersemans V, Kelly C, et al. Pre-clinical evaluation of a 3-nitro-1, 2, 4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET[J]. Nucl Med Biol, 2010, 37(5): 565-575.
[14]Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression[J]. Eur J Nucl Med Mol Imaging, 2003, 30(5): 695-704.
[15]Kawai N, Lin W, Cao WD, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas[J]. Eur J Nucl Med Mol Imaging, 2014, 41(10): 1870-1878.
[16]Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies[J]. J Nucl Med, 2006, 47(3): 410-418.
[17]Bokacheva L, Kotedia K, Reese M, et al. Response of HT29 colorectal xenograft model to cediranib assessed with 18F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI[J]. NMR Biomed, 2013, 26(2): 151-163.
[18]Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice[J]. Br J Cancer, 2004, 90(4): 906-910.
[19]Oehler C, O’Donoghue JA, Russell J, et al. 18F-Fluromisonidazole PET Imaging as a Biomarker for the Response to 5, 6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors[J]. J Nucl Med, 2011, 52(3): 437-444.
[20]Prekeges JL, Rasey JS, Grunbaum Z, et al. Reduction of fluoromisonidazole, a new imaging agent for hypoxia[J]. Biochem Pharmacol, 1991, 42(12): 2387-2395.
[21]Joseph P, Jaiswal AK, Stobbe CC, et al. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles[J]. Int J Radiat Oncol Biol Phys, 1994, 29(2): 351-355.
[22]Norikane T, Yamamoto Y, Maeda Y, et al. Correlation of(18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET[J]. Nucl Med Commun, 2014, 35(1): 30-35.
[23]Sato J, Kitagawa Y, Yamazaki Y, et al. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma[J]. J Nucl Med, 2013, 54(7): 1060-1065.
[24]Okamoto S, Shiga T, Yasuda K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer[J]. J Nucl Med, 2013, 54(2): 201-207.
[25]Lin Z, Mechalakos J, Nehmeh S, et al. The Influence of Changes in Tumor Hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography[J]. Int J Radiat Oncol Biol Phys, 2008, 70(4): 1219-1228.
[26]Alber M, Paulsen F, Eschmann SM, et al. On biologically conformal boost dose optimization[J]. Phys Med Biol, 2003, 48(2): N31-35.
[27]Grkovski M, Schwartz J, Rimner A, et al. Reproducibility of 18F-Fluoromisonidazole intratumour distribution in non-small cell lung cancer[J]. EJNMMI Res, 2016, 6(1): 79.
[28]Cheng J, Lei L, Xu J, et al. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance inbreast cancer[J]. J Nucl Med, 2013, 54(3): 333-340.
[29]Kikuchi M, Yamane T, Shinohara S, et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma[J]. Ann Nucl Med, 2011, 25(9): 625-633.